Tislelizumab is a humanized monoclonal antibody drug that belongs to PD-1 inhibitors. It activates the human immune system to attack tumor cells by blocking the PD-1/PD-L1 signaling pathway on the surface of tumor cells. At present, it is mainly used for the treatment of advanced solid tumors (such as non-small cell lung cancer, esophageal cancer, etc.) and hematological tumors (such as classical Hodgkin lymphoma).
1. Mechanism of action
Blocking the PD-1/PD-L1 pathway: Tumor cells bind to PD-1 of immune T cells through PD-L1, inhibiting T cell activity; Tagolizumab can block this process and restore T cell anti-tumor function.
Enhance immune response: By relieving immune suppression, promote the immune system to recognize and eliminate tumor cells.
2. Indications
Solid tumor: approved for advanced non-small cell lung cancer (second-line and above), esophageal squamous cell carcinoma (first-line combination chemotherapy), etc.
Hematological tumors: classic Hodgkin lymphoma (recurrent/refractory), etc.
3. Common side effects
Immune related reactions: such as pneumonia, hepatitis, colitis, etc. (require timely medical attention).
General adverse reactions: fatigue, rash, itching, decreased appetite, etc.
Infusion reactions: fever, chills, and difficulty breathing (with a low incidence).
4. Precautions
Use according to medical advice: strictly follow the dosage and cycle prescribed by the doctor, and do not adjust or stop medication on your own.
Monitoring adverse reactions: During treatment, regular checks of liver and kidney function, thyroid function, etc. are necessary. If serious side effects (such as persistent diarrhea and difficulty breathing) occur, medical attention should be sought immediately.
Taboo population: People who are allergic to drug ingredients, patients with active autoimmune diseases, pregnant and lactating women should use with caution.
5. Clinical efficacy
Existing studies have shown that Tagolizumab exhibits a high objective response rate and persistent response in some tumors, but the efficacy varies depending on individual differences and tumor types, and needs to be evaluated for applicability in combination with genetic testing.
Medical guidance: This medication is a prescription drug, and before use, it needs to be evaluated by a specialist oncologist for the condition, staging, and physical condition, and an individualized plan should be developed. Close follow-up is required during the treatment period to dynamically adjust medication strategies.
